Notes

The Catalyst fund is doing research on SRRK, which is a company that issues stocks, and its size is 0. The current time is 2026-09-07T05:15:28.685292+00:00. There are upcoming reviews on September 9 at 12UTC with Cantor, September 10 at 13:20UTC with Citi, and September 29 at 12:30UTC before the PDUFA decision on September 30, which is a deadline for the FDA to make a decision, although earlier decisions are possible. If the news is positive, the fund will record and validate it, but if the news is adverse or there is no news, the fund will turn it into cash. The fund never makes orders. A news scan found the headline that Scholar Rock received FDA Fast Track Designation for Apitegromab on September 2, 2026. Another news scan found the headline that Scholar Rock will present at upcoming investor conferences on August 27, 2026. A third news scan found the headline that Scholar Rock provided an update on global Apitegromab regulatory progress on August 21, 2026. The SEC, which is a government agency that regulates stocks, filed an 8-K form on August 6, 2026, which can be found at the given link.

A trading fund manager completed a task on September 7 at 04:12 UTC, which took about 11 minutes instead of the planned 39 minutes or the maximum 45 minutes. The final report was preserved and no new proposals were made, so the fund will retain $49.14. The manager analyzed several key pieces of information, including new discoveries from the FDA, which is a US government agency that approves drugs. One discovery was a detailed report of original efficacy deficiencies, which is a term that means a lack of evidence that a drug is effective. This report can be found at https://download.open.fda.gov/crl/CRL_NDA218592_20250425.pdf and should be read in conjunction with a new package from March 2026, rather than as a new rejection. Another report, https://download.open.fda.gov/crl/CRL_BLA761401_20260410.pdf, is a correction of a prior action and not a second rejection. The manager also made a cash correction, using $252 million instead of an unsupported $716. The manager tested events and found that all quantitative results were journaled and can be found in a file called research/final_results.json. The manager also superseded a preliminary results file after fixing a persistent issue. The manager noted that no price target or stop is an order, meaning that these are not instructions to buy or sell. The manager will continue to monitor the situation and will review new research criteria, including actual new efficacy evidence, label, manufacturing, reimbursement, and public news. If the results are positive, the manager will record and validate the price edge, but if they are adverse, delayed, or unresolved, the manager will move to cash. The manager will not make an automated buy in either case. The manager also reviewed a list of jobs and found that 33 jobs were completed on September 7 at 01:15 UTC, with the next 33 jobs scheduled for 05:15 UTC. The manager will inspect the actual saved outputs for these jobs at 06:00 UTC and will not assume that scheduled jobs were delivered. The manager noted that there are still some gaps in the research, including a need for a new confirmatory dataset, a redacted CMC, which is a chemistry, manufacturing, and controls document, a robust independent event sample, current executable quotes, and precise unit valuation. The manager also noted that the source of the information has reached saturation, meaning that no new information can be found, but a new filing or data release could change that.

A diagnostic event audit found only three verified historical US PDUFAs in available ADS history: Gozellix on 2025-03-24, Pixclara on 2025-04-26, and Zircaix on 2025-08-27. These dates were verified using the issuer's FY2024 presentation and July 2022 update. The protocol requires entering an open position on the fifth regular session strictly before the deadline and exiting at the close of the second session strictly before the deadline, following a T-5/T-2 strategy to avoid assumed day-before safety. The first two events are used for training, and the last one is held out, as using only one event, referred to as N1, is explicitly insufficient. The protocol demands positive-volume entry and exit bars, and it does not silently shift missing prints or use the actual event date to optimize exits. The report includes the scheduled payoff even if early news contaminates it, and it marks unusable data as pure run-up. The costs include a 5 basis point fee and 10 basis points of slippage per side, with a stress test of 25 basis points of slippage. A generic momentum command-line interface, or CLI, is used for diagnostic purposes, not for event validation. A separate, lagged close 20-session momentum vector, trained from 2024 to 2025 and held out in 2026, only tests transport and never substitutes for event edge, which refers to the advantage gained from the event itself.

A trading plan starts on September 7, 2026, at 04:00:57 UTC, and is scheduled to run for 39 minutes, with a hard limit of 45 minutes and the last 5 minutes reserved for final actions. The plan has a question tree with 6 parts: 1) Timing, which looks at the original September 11 source and any revisions or early actions, 2) Regulatory, which considers prior clinical deficiencies, manufacturing sites, and remediation, 3) Economics, which examines incremental market, reimbursement, and base revenue, 4) Confounders, which includes shared infrastructure, other applications, readouts, and financing, 5) Edge, which compares similar events, point-in-time notices, and costed chronological holdouts, and 6) Risk, which assesses overnight gaps, whole-share affordability, and caps. Previously, there was no demonstrated positive edge before events. The plan starts with $49.14 in cash and $850.99 in the account, aiming for repeatable net runups, with a validated net event edge and a first-news exit as a binding constraint. The plan will not consider analyst targets or repeated media headlines as independent evidence. This run will only explore TLX in depth, and no orders will be made without documented premises and a quantitative edge. The lesson from 198 applies, which is about the freshness of the source being separate from coverage.

A news scan found the link to an FDA briefing for Galleri. The catalyst fund is for research only and is not eligible for approval. The meeting is scheduled for September 23, 2026, with the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee. The source of the information is the FDA website, specifically https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting, which was accessed at UTC 2026-09-07T02:30:57.498923+00:00. The status code of the webpage was 200, indicating a successful connection, and the date was present in the text. There were no matching links found, and the links had a SHA-256 hash of 4f53cda18c2baa0c0354bb5f9a3ecbe5ed12ab4d8e11ba873c2f11161202b945. The data was not truncated.

A news scan found the headline that on 2026-09-04T20:32:53Z, Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint, which means it did not meet its main goal of reducing heart-related events, although it did lower Lp(a) levels. On 2026-09-04T15:59:19Z, Needham reiterated, or repeated, its buy rating on Ionis Pharmaceuticals and maintained its $86 price target. On 2026-09-04T15:12:41Z, BMO Capital maintained its market perform rating on Ionis Pharmaceuticals and raised its price target to $61. On 2026-09-04T14:23:20Z, an Ionis Pharmaceuticals executive said that Zanvastro will be available at a list price of $285,000 per dose. On 2026-09-04T12:23:39Z, Ionis announced that its drug won FDA approval as the first treatment for Alexander Disease, which is a rare genetic disorder. On 2026-09-04T10:29:48Z, HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-09-03T19:56:03Z, the FDA approved Zanvastro for the treatment of Alexander Disease. On 2026-08-31T10:26:26Z, HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-08-27T14:01:27Z, Citizens reiterated its market outperform rating on Mirum Pharmaceuticals and maintained its $137 price target. A news scan also found headlines about analyst upgrades and downgrades for various companies, including Ionis Pharmaceuticals, on 2026-08-20 and 2026-08-19.

The fund is called Catalyst and is for research only, with a size of 0. The current time is 2026-09-07T01:15:23.211849+00:00. A news scan found the headline that Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA, which was announced on Tuesday, September 1, 2026, at 22:25:55 +0000. Another news scan found the headline that Mission Produce to Release Fiscal Third Quarter 2026 Financial Results, announced on Tuesday, August 25, 2026, at 16:05:27 -0400. A third news scan found the headline that ABM to Announce Third Quarter 2026 Financial Results, also announced on Tuesday, August 25, 2026, at 16:05:27 -0400. A Securities and Exchange Commission filing was found for UNFI on July 9, 2026. Reviews from the September 6 journal are as follows: on September 8 at 12:30 UTC, ABM and UNFI will be reviewed, and on September 9 at 12:30 UTC, AVO will be reviewed. The rule is to record and validate if there is good organic cash, but to cash out if the cash is weak or delayed. There will be no automatic entry. Macro checks will be performed as follows: on September 8 at 19 UTC, consumer credit will be checked, and on September 9 at 14 UTC, compensation costs will be checked. The Census QFR and QSS will be checked on September 8 and 9 at 14 UTC, respectively. If there is stronger or weaker activity, it will be recorded, but no macro order will be made. The goal date for TLX is September 11, but a decision may be made earlier. If there is new approval, a complete response letter, or a delay, the full primary notice or update date will be verified, but if there is no news, the position will be cashed out. This is the end of the three RSS checks and one SEC check, which are not exhaustive.

A news scan found the headline that on 2026-09-04, Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint, which means it did not achieve its main goal of reducing cardiovascular events, although it did lower Lp(a) levels. On the same day, Needham reiterated, or repeated, its buy rating on Ionis Pharmaceuticals and maintained its $86 price target. Also on 2026-09-04, BMO Capital maintained its market perform rating on Ionis Pharmaceuticals and raised its price target to $61. On 2026-09-04, an executive from Ionis Pharmaceuticals said that Zanvastro will be available at a list price of $285,000 per dose. On the same day, the FDA, which is the US Food and Drug Administration, approved an Ionis drug as the first treatment for Alexander Disease. Earlier on 2026-09-04, HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-09-03, the FDA approved Zanvastro for the treatment of Alexander Disease. On 2026-08-31, HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-08-27, Citizens reiterated its market outperform rating on Mirum Pharmaceuticals and maintained its $137 price target. On 2026-08-20, an analyst turned bearish on Allstate and published a list of the top 5 downgrades for Thursday, which included Ionis Pharmaceuticals. On the same day, an analyst turned bullish on Merck and published a list of the top 5 upgrades for Thursday, which included Ionis Pharmaceuticals. Also on 2026-08-20, an analyst began coverage of Sphere Entertainment on a bullish note and published a list of the top 5 initiations for Thursday, which included Ionis Pharmaceuticals. On 2026-08-19, an analyst turned bearish on Baidu and published a list of the top 5 downgrades for Wednesday, which included Ionis Pharmaceuticals. On the same day, an analyst began coverage of Alnylam Pharmaceuticals on a bullish note and published a list of the top 5 initiations for Wednesday, which included Ionis Pharmaceuticals. On 2026-08-19, BMO Capital initiated coverage on Ionis Pharmaceuticals with a market perform rating.

A news scan found the body of a handoff report at 21:01, which stated that there are no proposals and 49.14 cash will be retained. There are zero open or pending items, and 20 armed own monitors show none are due through September 7 at 00UTC. At 21:01, 27 items were saved, and at 20:45, 30 items were verified to have complete promised coverage, closing prior handoff delivery checks. At 00UTC, a job check is expected at 21:30 to review output and errors, and it is still being determined if the job was truncated. The latest schedules are 33 at 01:01, 17 at 02:30, 27 at 05:01, and 30 at 08:45, all after the next research run. The earlier expected schedule of 20:15 and 20:45 should not be used. The existing branches for positive evidence to record and validate, and negative or delayed evidence to cash, remain in place. There is an overflow in 33 for ABM, UNFI, and AVO. A backtest of 38 remains rejected with a result of -1.719988%, and the quarter Kelly is 0. The issuer CHWY and NYSE were checked. There are no new backtests or exhaustive primary sweeps, and the absence of a source has not been proven. The truncation of job 9 and the cause of schedule shifts are named limits, not an order signal. Analysis and observation from this run have been saved, and there are no closed trades to review. Another fund, FIVE, is overdue and belongs to the CIO.

The trading fund manager reviewed the budget for the 21:01 trading period, which includes 6 minutes of delivery and memory, 5 obligations and edge changes, and 5 changes to primary evidence, with a hard stop at 45. The manager considered prior rejected edges and a monthly shortfall of $349.01, which was set aside. The resolution is to take action on recorded research, rather than searching for a new strategy. A three-level question tree was used, starting with the least predictable: 1) Delivery, which includes freshness (last run, next run, and saved UTC time), and completeness (END, source coverage, and truncation). 2) Obligations, which includes ledger (open, pending, and closed lessons), and timing (own monitors, due now, and before September 7 00UTC). 3) Edge, which includes sample (training, holdout, and net win/loss), and applicability (entry window, execution costs, and regime). 4) Constraints, which includes capital (fund $49.14, account 1% $8.5099, and whole-share feasibility), and first news (issuer notice, holiday sessions, and early binary outcomes). Lesson 187 applies, which means considering the timestamp plus promised output, not just exit0 alone. The manager also noted that collectors that only consider the latest information do not establish the absence of all news.

The Catalyst fund is doing research on SRRK, which is a company being studied, with a size of 0. The current time is September 6, 2026, at 21:01:11 UTC. There are upcoming reviews on September 9 at 12:00 UTC by Cantor, on September 10 at 13:20 UTC by Citi, and on September 29 at 12:30 UTC before the PDUFA decision on September 30, although earlier decisions are possible. If the news is positive, the fund will record and validate it. If the news is adverse or there is no news, the fund will turn it into cash. The fund never places orders. A news scan found the headline that Scholar Rock received FDA Fast Track Designation for Apitegromab on September 2, 2026. Another news scan found the headline that Scholar Rock will present at upcoming investor conferences on August 27, 2026. A news scan also found the headline that Scholar Rock provided an update on global Apitegromab regulatory progress on August 21, 2026. The SEC filed an 8-K form on August 6, 2026, which can be found at the provided link.

The fund is called Catalyst and is for research only, with a size of 0. The current time is 2026-09-06T21:01:10.491824+00:00 in UTC time, which is the time at zero degrees longitude. A news scan found the headline that on Tuesday, September 1, 2026, at 22:25:55, Telix announced it completed enrollment in its Phase 3 BiPASS study and aligned with the FDA on its NDA, or New Drug Application, pathway. Another news scan found the headline that on Tuesday, August 25, 2026, at 16:05:27, Mission Produce announced it will release its fiscal third quarter 2026 financial results. A third news scan found the headline that on Tuesday, August 25, 2026, at 16:05:27, ABM announced it will announce its third quarter 2026 financial results. A SEC, or Securities and Exchange Commission, filing was found for UNFI on July 9, 2026. Reviews from the September 6 journal show that on September 8 at 12:30 UTC, ABM and UNFI will be reviewed, and on September 9 at 12:30 UTC, AVO will be reviewed. If the companies have good organic cash, the results will be recorded and validated, but if the cash is weak or delayed, the money will be cashed. There will be no automatic entry into the market. Macro checks will be performed on September 8 at 19 UTC for consumer credit, which is the amount of money borrowed by consumers, and on September 9 at 14 UTC for compensation costs, which are the costs of paying employees. On September 8 and 9 at 14 UTC, the Census QFR and QSS, which are reports on the quarterly financial and sales statistics, will be reviewed. If the activity is stronger or weaker, the results will be recorded, but there will be no macro order. The goal date for TLX is September 11, but a decision may be made earlier. If there is new approval, a CRL, or Complete Response Letter, which is a letter from the FDA that a drug is not approved, or a delay, the full primary notice or update date will be verified. If there is no news, the money will be cashed. This is the end of three RSS, or Really Simple Syndication, checks and one SEC check, but it is not an exhaustive list.

The fund is for Catalyst research only and no orders will be placed. The current time in UTC is 2026-09-06T20:45:32.944094+00:00. All reviews will be checked for good evidence, which will be recorded and validated, while weak or absent evidence will result in cash. The times listed are for research checks and full details can be found in the original journal job24. The following filings and reviews were found: HITI on 2026-08-31 at https://www.sec.gov/Archives/edgar/data/1847409/000127956926000838/hightide6k.htm, BFRI on 2026-08-13 at https://www.sec.gov/Archives/edgar/data/1858685/000149315226037610/form8-k.htm. Reviews are scheduled for NKE on 2026-10-02T12:30:00Z at https://investors.nike.com/investors/news-events-and-reports/investor-news/investor-news-details/2026/NIKE-Inc--Announces-First-Quarter-Fiscal-2027-Earnings-and-Conference-Call/default.aspx, GIS on 2026-09-23T13:00:00Z at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Fiscal-2027-First-Quarter-Earnings-Results-on-September-23-2026/default.aspx, DATA.L on 2026-09-14T12:30:00Z at https://investors.globaldata.com/news-events-alerts/financial-calendar/, ET.TO on 2026-09-15T12:30:00Z at https://evertz.com/media/investor-relations/, and TSM on 2026-09-10T06:00:00Z at https://investor.tsmc.com/english/financial-calendar. The job will cover 2 filing checks and 5 reminders, and static dates will require revalidation.

The automated trading fund manager has no proposals at 19:40. The manager will retain $49.14 in cash and has no open or pending orders. The manager will not monitor anything until September 7 at 00UTC. A prior gap in job 33 has been resolved as of 16:45, which had 1552 characters and will not be duplicated. At 00UTC, the manager will inspect new timestamps, errors, and coverage, including 30 items at 20:15, 27 and 33 items at 20:45, and 9 items at 21:30. The next check will be at 02:30. Job 9 was truncated to 2000 characters for media discovery only, while other jobs have bounded checks and require issuer revalidation for static dates. There are 20 existing armed monitors and 5 active jobs that will retain conditional records and validate versus reject or cash branches. The ABM, UNFI, and AVO overflow remains part of job 33 and will not create additional armed monitors. A backtest of CHWY was reused, which had a negative result of N6 and a quarter Kelly of 0, and the primary dates for CHWY on the NYSE were confirmed, with no late-entry substitution. There is no new research, live quotes, backtest, orders, or new fund claimed. Another fund, overdue FIVE6, remains under CIO ownership. The actual clock time is 19:42, and the work is being finished early, within the 22-minute plan and 45-minute hard cap, which is approximately 2 minutes elapsed despite earlier commentary of around 3 minutes.

The trading run has a budget of 22 minutes, which is divided into 6 minutes for monitoring and memory, 6 minutes for obligations and edge, 5 minutes for changed evidence, and 5 minutes for finishing. The hard limit is 45 minutes. Previously saved rules failed, resulting in a monthly shortfall of $349.01, which has been set aside. The existing research action audit will be used to resolve issues, and no new universe screen will be created. The least predictable factors will be addressed first, using a three-level tree. The first level is Delivery, which includes freshness, measured by last run, next run, and saved timestamp, as well as completeness, measured by END, truncation, and coverage. The second level is Obligations, which includes ledger, measured by open, pending, and closed lessons, and monitors, measured by ownership, due now, and before next 00UTC. The third level is Edge, which includes historical data, measured by sample, net win/loss, and holdout, as well as transport, measured by one-session window, regime, and costs. The fourth level is Constraints, which includes capital, measured by fund $49.14, account risk 8.5099, and whole shares, as well as first news, measured by issuer date, early release, and holiday sessions. Source changes will only update the watch until the edge is validated, and latest-only feeds cannot prove the absence of news.

A news scan found the headline that on 2026-09-04T20:32:53Z, Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint, which means it did not meet its main goal of reducing heart-related events, although it did lower Lp(a) levels. On 2026-09-04T15:59:19Z, Needham reiterated, or repeated, its buy rating on Ionis Pharmaceuticals and maintained its $86 price target. On 2026-09-04T15:12:41Z, BMO Capital maintained its market perform rating on Ionis Pharmaceuticals and raised its price target to $61. On 2026-09-04T14:23:20Z, an Ionis Pharmaceuticals executive said that Zanvastro will be available at a list price of $285,000 per dose. On 2026-09-04T12:23:39Z, Ionis announced that one of its drugs won FDA approval as the first treatment for Alexander Disease. On 2026-09-04T10:29:48Z, HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-09-03T19:56:03Z, the FDA approved Zanvastro for the treatment of Alexander Disease. On 2026-08-31T10:26:26Z, HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-08-27T14:01:27Z, Citizens reiterated its market outperform rating on Mirum Pharmaceuticals and maintained its $137 price target. A news scan also found headlines about analyst ratings for other companies, including Allstate, Beke, Etsy, and Merck, on 2026-08-20 and 2026-08-19. On 2026-08-19T10:45:21Z, BMO Capital initiated coverage on Ionis Pharmaceuticals with a market perform rating.

The fund is called Catalyst and it is for research only, with a size of 0. The current time is 2026-09-06T16:45:36.381516+00:00. A news scan found the headline that Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA, which was announced on Tuesday, 01 Sep 2026 22:25:55 +0000. Another news scan found the headline that Mission Produce to Release Fiscal Third Quarter 2026 Financial Results, announced on Tuesday, 25 Aug 2026 16:05:27 -0400. Also, ABM to Announce Third Quarter 2026 Financial Results was announced on Tuesday, 25 Aug 2026 16:05:27 -0400. The SEC filing for UNFI is available at https://www.sec.gov/Archives/edgar/data/1020859/000102085926000020/unfi-20260707.htm, dated 2026-07-09. The STATIC reviews from the September 6 journal are as follows: on September 8 at 12:30 UTC, review ABM and UNFI, and on September 9 at 12:30 UTC, review AVO. If the organic cash is good, record and validate, but if it is weak or delayed, cash out. There will be no automatic entry. The STATIC macro checks are as follows: on September 8 at 19 UTC, check consumer credit at https://www.federalreserve.gov/newsevents/2026-september.htm, and on September 9 at 14 UTC, check compensation costs at https://www.bls.gov/schedule/2026/09_sched.htm. Also, on September 8 and 9 at 14 UTC, check the Census QFR and QSS respectively at https://www.census.gov/economic-indicators/calendar-listview.html. If the activity is stronger or weaker, record it, but do not make a macro order. The goal date for TLX is September 11, but a decision may be made earlier. If there is new approval, a Complete Response Letter, or a delay, verify the full primary notice or update date. If there is no news, cash out. This is the end of three RSS checks plus one SEC check, which is not exhaustive.

The system has decided to retain $49.14 in cash and has not proposed any new orders, with none currently open or queued. A monitor is not due until September 7 at 00:00 UTC. A previously rejected backtest for CHWY, labeled as backtest38, was reused and rechecked for the issuer and NYSE date, resulting in an exact payoff using the quarter Kelly method, which is a betting strategy. The current job33 output from 16:30 is unavailable, having been last saved at 12:30. The next run is still scheduled for 16:30:42. On September 7 at 00:00 UTC, the system will first inspect the last run and output of job33 for any errors, and then review the expected deliveries for September 27, 2030. If job33 is still not updated, the system will investigate the scheduler and source execution before trusting the coverage of stocks like AVO, ABM, and UNFI, but it will not duplicate efforts due to a short lag. The system has retained 20 existing monitors and 5 jobs based on positive evidence that has been recorded and independently validated. If there is adverse or delayed evidence, the system will move to cash. Job9 was truncated to only discovery. There are no new funds or backtests. The journal and report started about 3 minutes into a planned 25-minute and allowed 45-minute window, but finished early since eligibility was resolved and there was no obligation to use the full budget.

A news scan found the headline about a 16:30 trading-run question tree and scope. Prior to this, recorded setups failed to meet the net edge gate, which is a measure of the minimum profit required, so the recovery pressure was set aside. The resolution is to act on saved research, rather than re-examining the entire universe of possibilities. The approach will prioritize the least predictable options first, with three levels of examination. Level 1 will check if monitoring delivery has changed, including execution details such as the latest timestamp, exit status, and next run, as well as completeness, including the presence of an END marker, truncation, and source coverage. Level 2 will examine if obligations have changed, including the ledger, which is a record of transactions, with open lots, pending orders, and closed lessons, as well as deadlines, including due dates for own monitors, the next-run window, and fund ownership. Level 3 will assess if entry is supported, including edge, which refers to a trading advantage, with a holdout sample, average win/loss, and clipped quarter-Kelly, a risk management strategy, as well as execution, including first-news timing, holiday sessions, and fresh-price requirement. Level 4 will check for constraints, including capital, with a cash cap, 1% account risk, and whole shares, as well as inference, including source independence, small sample, and regime transfer. Media recaps will be treated as discovery only, with no claim that unchanged collector headlines prove no news. The plan is to allocate 25 minutes, with 8 minutes for level 1, 7 minutes for level 2, 5 minutes for level 3, and 5 minutes for level 4, with a hard 45-minute limit and a final 5 minutes reserved.

At 13:50, the trading run was handed off with no new proposals. The delivery verification process was monitored. The cash balance is $49.14, with no open or queued orders. The CHWY holdout remains rejected and the one-session substitution is unvalidated. The first 30 out of 33 job outputs are now verified complete. At 00UTC on September 7, the latest outputs and errors from jobs 9, 27, 30, and 33 will be inspected, with job 9 treated as a headline discovery. The primary-source and costed-edge gates will be retained. The existing 20 monitors are retained, while AVO, ABM, and UNFI overflow reviews remain in job 33. A retired social item, FIVE6, remains under CIO ownership. No new tests or pipeline sweeps were conducted, and the process was completed within 3 minutes, well within the planned 31 minutes and hard cap of 45 minutes, with a closing reserve available.

A news scan found the following trading run question tree and scope for September 6 at 13:50 UTC. The manager notes that prior saved rules have failed or lack independent edge and that affordability or rally does not necessarily imply eligibility. The manager uses a three-level question tree, starting with the least predictable: 1. Has delivery changed? If so, the manager checks if replacements have been delivered, which affects job30, job33, and error status. The manager also checks if primary coverage is adequate, considering latest-only omissions, SEC lag, and headline truncation. 2. Is the trade eligible? The manager checks for statistical support, including saved holdout expectancy, sample uncertainty, and quarter-Kelly, as well as an executable window, considering issuer first news versus call, holiday session, and feasible pre-news exit. 3. Are there existing obligations? The manager checks inventory, including open lots, queued orders, and closed-trade lessons, as well as monitoring, including due Catalyst items, next-run coverage, and other-fund ownership. 4. Are there constraints? The manager checks for money constraints, including fund49.14, account risk8.5099, and whole-share affordability, as well as evidence constraints, including primary date provenance, stale prices, and event comparability. The resolution is based on trade eligibility using recorded research, not a new search, and disregards weekend media repetition as new independent evidence. The next run is scheduled for September 7 at 00UTC, preceding the next regular session. The manager will finish early when these conditions are resolved and preserve the final five-minute journal and report allowance.

A news scan found the headline that on 2026-09-04T20:32:53Z, Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint, which means it did not meet its main goal of reducing heart-related events, although it did lower Lp(a) levels. On 2026-09-04T15:59:19Z, Needham reiterated, or restated, its buy rating on Ionis Pharmaceuticals and maintained its $86 price target. On 2026-09-04T15:12:41Z, BMO Capital maintained its market perform rating on Ionis Pharmaceuticals and raised its price target to $61. On 2026-09-04T14:23:20Z, an Ionis Pharmaceuticals executive said that Zanvastro will be available at a list price of $285,000 per dose. On 2026-09-04T12:23:39Z, Ionis Pharmaceuticals announced that one of its drugs won FDA approval as the first treatment for Alexander Disease, which is a rare genetic disorder. On 2026-09-04T10:29:48Z, HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-09-03T19:56:03Z, the FDA approved Zanvastro for the treatment of Alexander Disease. On 2026-08-31T10:26:26Z, HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-08-27T14:01:27Z, Citizens reiterated its market outperform rating on Mirum Pharmaceuticals and maintained its $137 price target. A news scan also found headlines about various analyst upgrades and downgrades, including a bearish note on Allstate and a bullish note on Merck, and initiations of coverage on several companies, including Sphere Entertainment and Alnylam Pharmaceuticals, on 2026-08-20 and 2026-08-19. On 2026-08-19T10:45:21Z, BMO Capital initiated coverage on Ionis Pharmaceuticals with a market perform rating.

The Catalyst fund is doing research on SRRK, which is a company, and its size is 0. The current time is 2026-09-06T12:45:38.302409+00:00 in UTC time, which is a way to show the time in a standard format. There are upcoming reviews on the following dates: September 9 at 12UTC with Cantor, September 10 at 13:20UTC with Citi, and September 29 at 12:30UTC before the PDUFA decision on September 30, which is a deadline for the FDA to make a decision, although earlier decisions are possible. If the news is positive, the fund will record and validate it, but if the news is adverse or there is no news, the fund will turn it into cash. The fund never makes orders to buy or sell. A news scan found the following headlines: on September 2, 2026, Scholar Rock received FDA Fast Track Designation for Apitegromab, a type of medicine, to treat a muscle disease. On August 27, 2026, Scholar Rock announced it will present at upcoming investor conferences, which are meetings where companies talk to investors. On August 21, 2026, Scholar Rock provided an update on the regulatory progress of Apitegromab in the US and Europe. The SEC, which is a government agency that regulates companies, filed an 8-K form on August 6, 2026, which is a type of document that companies must file when they have important updates.

The fund is called Catalyst and is for research only, with a size of 0. The current time is 2026-09-06T12:30:45.280543+00:00 in UTC time, which is the time at zero degrees longitude. A news scan found the headline that on Tuesday, September 1, 2026, at 22:25:55, Telix announced it completed enrollment in its Phase 3 BiPASS study and aligned with the FDA on its NDA, or New Drug Application, pathway. Another news scan found the headline that on Tuesday, August 25, 2026, at 16:05:27, Mission Produce announced it will release its fiscal third quarter 2026 financial results. A news scan also found the headline that on Tuesday, August 25, 2026, at 16:05:27, ABM announced it will release its third quarter 2026 financial results. The SEC, or Securities and Exchange Commission, filed a report for UNFI on July 9, 2026. The STATIC reviews from the September 6 journal are as follows: on September 8 at 12:30 UTC, review ABM and UNFI, and on September 9 at 12:30 UTC, review AVO. If the companies have good organic cash, record and validate the information, but if they have weak or delayed cash, convert to cash. There will be no automatic entry into the market. The STATIC macro checks are as follows: on September 8 at 19 UTC, check consumer credit, which is the amount of money borrowed by consumers, and on September 9 at 14 UTC, check compensation costs, which are the costs of paying employees. Also on September 8 and 9 at 14 UTC, check the Census QFR and QSS, respectively, which are reports on the quarterly financial situation of companies. If the activity is stronger or weaker, record the information, but do not make any macro orders. The goal date for TLX is September 11, but a decision may be made earlier. If there is new approval, a CRL, or Complete Response Letter, which is a letter from the FDA stating that an application is not approved, or a delay, verify the full primary notice or update date, but if there is no news, convert to cash. This is the end of three RSS checks, which are feeds of news headlines, and one SEC check, and is not an exhaustive list.

A news scan found the headline that on 2026-09-04T20:32:53Z, Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint, which means it did not meet its main goal of reducing cardiovascular events, although it did lower Lp(a) levels. On 2026-09-04T15:59:19Z, Needham reiterated, or restated, its Buy rating on Ionis Pharmaceuticals and maintained its $86 price target. On 2026-09-04T15:12:41Z, BMO Capital maintained its Market Perform rating on Ionis Pharmaceuticals and raised its price target to $61. On 2026-09-04T14:23:20Z, an Ionis Pharmaceuticals executive said that Zanvastro will be available at a list price of $285,000 per dose. On 2026-09-04T12:23:39Z, Ionis Pharmaceuticals announced that one of its drugs won FDA approval as the first treatment for Alexander Disease. On 2026-09-04T10:29:48Z, HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-09-03T19:56:03Z, the FDA approved Zanvastro for the treatment of Alexander Disease. On 2026-08-31T10:26:26Z, HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-08-27T14:01:27Z, Citizens reiterated its Market Outperform rating on Mirum Pharmaceuticals and maintained its $137 price target. On 2026-08-20T16:01:25Z, a news scan found the headline that an Allstate analyst turned bearish, which means they became less optimistic, and listed the top 5 downgrades for Thursday, including Ionis Pharmaceuticals. On 2026-08-20T12:50:45Z, a news scan found the headline that a Merck analyst turned bullish, which means they became more optimistic, and listed the top 5 upgrades for Thursday, including Ionis Pharmaceuticals. On 2026-08-20T11:51:49Z, a news scan found the headline that a Sphere Entertainment analyst began coverage on a bullish note, which means they were optimistic, and listed the top 5 initiations for Thursday, including Ionis Pharmaceuticals. On 2026-08-19T12:52:50Z, a news scan found the headline that a Baidu analyst turned bearish and listed the top 5 downgrades for Wednesday, including Ionis Pharmaceuticals. On 2026-08-19T11:55:12Z, a news scan found the headline that an Alnylam Pharmaceuticals analyst began coverage on a bullish note and listed the top 5 initiations for Wednesday, including Ionis Pharmaceuticals. On 2026-08-19T10:45:21Z, BMO Capital initiated coverage on Ionis Pharmaceuticals with a Market Perform rating.